Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dornstadt – page 58

718 clinical trials in Dornstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dornstadt at a glance
718
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

718 trials in Dornstadt

Open in trial search

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Study of RO7247669 and Nab-Paclitaxel vs. Pembrolizumab and Nab-Paclitaxel for Patients with Untreated, PD-L1 Positive, Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Status epilepticus

Not recruiting

Study on Ganaxolone for Patients with Refractory Status Epilepticus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ganaxolone
  • Sponsor:Marinus Pharmaceuticals Inc.

Diabetic retinopathy

Not recruiting

Study on BI 764524 for Patients with Moderate to Severe Diabetic Retinopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 764524
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Asciminib Treatment for Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Study on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Oncolytics Biotech Inc.

Status epilepticus

Not recruiting

Study on Treating Status Epilepticus in Seniors Using Levetiracetam and Valproate Semisodium

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Levetiracetam
  • Sponsor:University of Leipzig

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dornstadt

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on ulcerative colitis treatment approaches. The trials evaluate novel oral therapeutic solutions aimed at achieving symptomatic remission and improving endoscopic outcomes in patients with mild to moderate disease activity.

  • Inflammatory Bowel Disease Management
  • Controlled Release Drug Delivery
  • Long-term Disease Control

These studies represent significant advances in developing targeted treatments for gastrointestinal inflammatory conditions, with potential benefits for patient quality of life and disease management strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.